Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD Patients

Table 4

Patients’ characteristics with positive SARS-CoV-2 Ig tests. Patients in bold were swab test positive.

Patients	Age in years	Sex	Disease	Therapy	Symptoms	Travel history
A. K.	30	Female	CD	Infliximab every 8 weeks i.v.	Cough, rhinitis	Sri Lanka 03/2020
A. S.	53	Male	CD	Infliximab every 8 weeks i.v.	Headache, limb pain, anosmia
E. M.	49	Male	CD	Budesonide p.o.	Sore throat, fever	Austria 03/2020
M. C.	32	Female	CD	Infliximab every 8 weeks i.v.	Cough, rhinitis, headache, dyspnea	Egypt 03/2020
P. C.	45	Female	CD	Infliximab every 6 weeks i.v.	Cough, limb pain, dyspnea, abdominal pain and shingles
R. C.	29	Female	CD	Adalimumab 40 mg every 2 weeks s.c.	Cough, rhinitis, sore throat, abdominal pain	Austria 03/2020
W. F.	46	Male	CD	Ustekinumab 90 mg every 8 weeks s.c. plus 50 mg azathioprine daily p.o.	Cough, rhinitis, sore throat, abdominal pain	Netherlands 02/2020
B. P.	45	Male	UC	Mesalazine daily p.o.	Cough, rhinitis, sore throat	Austria 02/2020
C. M.	29	Female	UC	Adalimumab 80 mg every 2 weeks s.c.	Cough, chills
R. V.	29	Female	UC	Vedolizumab 300 mg every 8 weeks i.v.	Cough, sore throat, chills
R. R.	36	Male	UC	Infliximab every 8 weeks i.v.	Cough, sore throat
S. M.	36	Male	UC	Vedolizumab 300 mg every 8 weeks i.v.	Cough, rhinitis, expectoration
S. V.	79	Male	UC	Infliximab every 8 weeks i.v.	Fatigue, loss of wight
W. M.	29	Female	UC	Mesalazine daily p.o.	Cough, rhinitis, fatigue